01.27.26 -- Trump's Big Pharma Deals Drive CDMO Investments

Ensure your cell therapy program is prepared for the future by learning how to effectively navigate sourcing, logistics, and manufacturing challenges with confidence.

Review the elements of a complex process, prone to misconceptions and pitfalls, to find the “right human tissue” that will yield the desired cell quality and quantity and pass BLA approval.

Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.

The industry remains far from realizing a manufacturing platform with a repeatable, standardized process that can support broad clinical and commercial deployment.

While clinical efficacy is the critical benchmark for any drug program, ensuring manufacturability is also vital. An experienced CDMO can help you establish efficient and cost-effective production strategies.

Experience the benefits of faster, more effective CAR-T cell production with this innovative three-day short-cycle process, designed to enhance patient treatment outcomes while reducing costs.

RNA sequence and guide modifications, delivery platform design, and dose optimization all contribute to gene editing outcomes, which offer a clearer path toward more potent mRNA-based therapeutics.

Explore how a platform compares data to traditional qPCR, p24 ELISA, and TU assays in measuring both physical and functional titers.

Scalable lentiviral vector production is moving beyond adherent systems. Learn how workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.

Improve RNA production with a next-generation T7 RNA polymerase designed to minimize dsRNA, boost expression, and lower capping costs for better therapeutic outcomes.

See insights into an AAV manufacturing platform designed to achieve short timelines and cost-effective scalability for producing clinical trial and commercial material in bioreactors up to 2000 L.

A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.

With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, view how this company delivers speed and reliability to help cure patients faster.

From development through manufacturing, specialized CDMO capabilities support the next generation of biological modalities.

Accelerate your gene therapy pipeline with our cost-effective, high-quality lentiviral vectors, optimized for clinical and commercial success.

Delve into cell and gene manufacturing capacity designed to support faster development and stronger readiness for therapeutic programs.

With our top-tier services, reliable expertise, and global network of laboratories, we provide unparalleled support to improve countless lives.

In cell and gene therapies, your process is the product. Our team of experts develops, defines, and refines processes for maximum efficiency and scale.